Demonstrates a novel method for synthesizing erythrina alkaloids, highlighting enzyme-mediated selectivity and implications for bioactive compound development.
Direct selective C–H oxidation poses a significant challenge in natural product synthesis. Enzymes serve as enabling catalysts to precisely control the transformation with high chemo-, regio-, and stereoselectivity. In this study, we report the screening and engineering of a P450 BM3 variant capable of selective hydroxylation in the tricyclic core of erythrina alkaloids with high diastereoselectivity. To further address the enantioselectivity to construct the chiral α-tertiary amine, an enzymatic kinetic resolution by relay oxidation with engineered P450 BM3 and aldo-keto reductase was successfully implemented, utilizing a highly enantioselective aldo-keto reductase, resulting in the chiral intermediate, which has been successfully applied to the synthesis of 3-demethoxyerythratidinone. The selectivity modulation not only deepens our understanding of enzyme-catalyzed non-natural chemical transformations but also inaugurates an alternative synthetic route for bioactive molecules.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: